RaQualia Pharma Inc. (TYO:4579)

RaQualia Pharma Statistics

Total Valuation

RaQualia Pharma has a market cap or net worth of JPY 23.39 billion. The enterprise value is 23.05 billion.

Market Cap	23.39B
Enterprise Value	23.05B

Important Dates

The last earnings date was Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

RaQualia Pharma has 26.02 million shares outstanding. The number of shares has increased by 11.14% in one year.

Current Share Class	26.02M
Shares Outstanding	26.02M
Shares Change (YoY)	+11.14%
Shares Change (QoQ)	+5.91%
Owned by Insiders (%)	12.52%
Owned by Institutions (%)	-7.41%
Float	17.40M

Valuation Ratios

The trailing PE ratio is 79.14.

PE Ratio	79.14
Forward PE	n/a
PS Ratio	5.88
PB Ratio	3.39
P/TBV Ratio	7.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 23.71, with an EV/FCF ratio of -54.64.

EV / Earnings	84.38
EV / Sales	5.79
EV / EBITDA	23.71
EV / EBIT	47.64
EV / FCF	-54.64

Financial Position

The company has a current ratio of 4.46, with a Debt / Equity ratio of 0.42.

Current Ratio	4.46
Quick Ratio	4.06
Debt / Equity	0.42
Debt / EBITDA	2.99
Debt / FCF	-6.88
Interest Coverage	8.19

Financial Efficiency

Return on equity (ROE) is 4.38% and return on invested capital (ROIC) is 4.99%.

Return on Equity (ROE)	4.38%
Return on Assets (ROA)	3.00%
Return on Invested Capital (ROIC)	4.99%
Return on Capital Employed (ROCE)	5.24%
Weighted Average Cost of Capital (WACC)	7.96%
Revenue Per Employee	62.19M
Profits Per Employee	4.27M
Employee Count	64
Asset Turnover	0.39
Inventory Turnover	4.35

Taxes

In the past 12 months, RaQualia Pharma has paid 164.83 million in taxes.

Income Tax	164.83M
Effective Tax Rate	37.64%

Stock Price Statistics

The stock price has increased by +127.02% in the last 52 weeks. The beta is 0.83, so RaQualia Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	+127.02%
50-Day Moving Average	1,018.22
200-Day Moving Average	725.92
Relative Strength Index (RSI)	38.89
Average Volume (20 Days)	410,320

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RaQualia Pharma had revenue of JPY 3.98 billion and earned 273.12 million in profits. Earnings per share was 11.36.

Revenue	3.98B
Gross Profit	3.27B
Operating Income	483.72M
Pretax Income	437.95M
Net Income	273.12M
EBITDA	971.88M
EBIT	483.72M
Earnings Per Share (EPS)	11.36

Balance Sheet

The company has 3.24 billion in cash and 2.90 billion in debt, with a net cash position of 342.38 million or 13.16 per share.

Cash & Cash Equivalents	3.24B
Total Debt	2.90B
Net Cash	342.38M
Net Cash Per Share	13.16
Equity (Book Value)	6.90B
Book Value Per Share	281.96
Working Capital	4.41B

Cash Flow

In the last 12 months, operating cash flow was -354.43 million and capital expenditures -67.35 million, giving a free cash flow of -421.78 million.

Operating Cash Flow	-354.43M
Capital Expenditures	-67.35M
Free Cash Flow	-421.78M
FCF Per Share	-16.21

Margins

Gross margin is 82.11%, with operating and profit margins of 12.15% and 6.86%.

Gross Margin	82.11%
Operating Margin	12.15%
Pretax Margin	11.00%
Profit Margin	6.86%
EBITDA Margin	24.42%
EBIT Margin	12.15%
FCF Margin	n/a

Dividends & Yields

RaQualia Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.14%
Shareholder Yield	-11.14%
Earnings Yield	1.17%
FCF Yield	-1.80%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RaQualia Pharma has an Altman Z-Score of 3.29 and a Piotroski F-Score of 6.

Altman Z-Score	3.29
Piotroski F-Score	6